EMA: review of hydroxyprogesterone started

Asset Publisher

EMA: review of hydroxyprogesterone started

EMA has started a review of medicines containing hydroxyprogesterone following concerns about the safety and effectiveness of these medicines.

Published on: 12 May 2023

Asset Publisher

Site Map

Safety of medicinal products

Share

Nested Applications

Highlights

29/10/2025 - Board of Directors meeting of October 28, 2025, medicines eligible for reimbursement

09/10/2025 - Medicines approved for reimbursement by the AIFA Board of Directors. These include two new molecules, three generics, three biosimilars and an extension of therapeutic indication

ALL NEWS

News

29/10/2025

Monitoring of Pharmaceutical expenditure - January / May 2025

29/10/2025

Direct communication with healthcare professionals on Lenalidomide Mylan

29/10/2025

Hepatitis C: update of 27 October 2025 concerning enrolled patients

All news

Galleria

Nested Applications

Press

Board of Directors meeting of October 28, 2025, medicines eligible for reimbursement

All press releases

Last tweets

È iniziato il conto alla rovescia per la #MedSafetyWeek di quest'anno ⏱️ 🔗 Clicca sul link in bio p...

Vai al post →

📆 Dalla prossima settimana unisciti a noi per la decima edizione della #MedSafetyWeek! 🌎 118 Paes...

Vai al post →

🤝 Incontro istituzionale tra il Presidente di #AIFA Robert Nisticò e il Capo dell’Autorità Egiziana...

Vai al post →

🤝 Ad Amsterdam l’incontro istituzionale tra #AIFA e Taiwan FDA. 📚 Durante il Summit 2025 della Co...

Vai al post →

Ciprofloxacina, levofloxacina, moxifloxacina: nomi forse poco familiari, ma che indicano una classe ...

Vai al post →

📊 Online il Rapporto AIFA 2024 La pubblicazione presenta i dati e le attività principali del 2024 a...

Aifa toggle bar Search

Aifa toggle bar Search